NEXIMMUNE INC (NEXI)

Company Profile

Neximmune Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Gaithersburg, Maryland and currently employs 50 full-time employees. The company went IPO on 2021-02-12. NexImmune, Inc. is a clinical-stage biotechnology company. The firm is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML) and NEXI-002 in multiple myeloma (MM). The firm provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company’s T cell product candidates are designed to combine the attributes of cellular with reduced potential for toxicities. The company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.

Company Info

NEXIMMUNE INC

9119 Gaither Road

Gaithersburg MARYLAND 20878

P: 13018259810

CEO: Scott Carmer

Employees: 50

Website: https://www.neximmune.com/